Metropolis Healthcare spurted 6.08% to Rs 1,897 after the company said it achieved highest ever quarterly revenue in Q2 September 2020.
The revenue for Q2 September 2020 (Q2FY21) has nearly doubled from Q1 June 2020 (Q1FY21) and has grown by about 25% from Q2 September 2019 (Q2FY20) levels.In September 2020, revenue growth stood at approximately 40% compared with September 2019.
The number of patient visits for Q2FY21 stood at approximately 2.41 million compared to 1.37 million in Q1FY21 and 2.66 million in Q2FY20. The number of tests for Q2FY21 stood at approximately 4.35 million compared to 2.65 million in Q1FY21 and 5.17 million in Q2FY20.
The company has reached about 85% of last year levels in Q2FY21 for non-covid business and in comparison to 71% in Q1FY21. In September 2020, the company has achieved normalcy in non-covid business compared to September 2019.
"With scale-up of non-covid business, sustained cost management measures as well as operating leverage on-account of significant uptick in revenue, the EBITDA margins in Q2FY21 has improved over Q2FY20," the company said in a statement.
The company said it continues to be a net cash company with cash and cash equivalents of approximately Rs 300 crore at the end of 30 September 2020.
The scrip has zoomed 90.99% from its 52-week low of Rs 993.20 hit on 24 March 2020.
The medical diagnostics company's consolidated net profit slumped 89.3% to Rs 2.88 crore on 29.6% drop in net sales to Rs 143.13 crore in Q1 June 2020 over Q1 June 2019.
Metropolis Healthcare is a diagnostics company with presence across 19 states in the country. The company's network as of 31 March 2020 consists of 124 laboratories and 2,731 patient service centers.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU